Abstracts Archive - Page 1925 of 2425 - ACR Meeting Abstracts

Abstract Number: 1926 • 2014 ACR/ARHP Annual Meeting
Nailfold Videocapillaroscopy Patterns Associated with Calcinosis and Acro-Osteolysis in Systemic Sclerosis
Jerome Avouac¹, Laetitia Morardet², Maya Sammour³, Andre Kahan², Antoine Feydy³ and Yannick Allanore¹, ¹Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ²Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ³Paris Descartes University, Radiology B department, Cochin Hospital, Paris, France
Background/Purpose: Calcinosis and acro-osteolysis are frequent in systemic sclerosis (SSc). They may be related to digital vasculopathy, which can be assessed by nailfold videocapillaroscopy (NVC).…
Abstract Number: 1925 • 2014 ACR/ARHP Annual Meeting
Determinants of Blood Hydroxychloroquine Concentration Variations in Systemic Lupus Erythematosus Patients
Moez Jallouli¹, Lionel Galicier², Olivier Aumaître³, Camille Francès⁴, Véronique Le-Guern⁵, F. Lioté⁶, Amar Smail⁷, Nicolas Limal⁸, L. Perard⁹, H. Desmurs-Clavel¹⁰, Du Boutin¹¹, B. Asli¹², Jean Emmanuel Kahn¹³, Jacques Pourrat¹⁴, Laurent Sailler¹⁵, F. Ackermann^1,13, T. Papo¹⁶, Karim Sacre¹⁷, O. Fain¹⁸, J. Stirnemann¹⁸, Patrice Cacoub¹⁹, Gaëlle Leroux²⁰, Judith Cohen-Bittan²¹, Js Hulot²², Zahir Amoura²³, Jean-Charles Piette²⁴ and Nathalie Costedoat-Chalumeau²⁵, ¹Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ²Internal Medicine, Hopital St Louis, AP-HP, Paris, France, ³Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, ⁴service de dermatologie allergologie, Hôpital Tenon, Paris Cedex 20, France, ⁵service de médecine interne, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁶service de rhumatologie, Hôpital Lariboisière, Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France, ⁷Internal Medicine Department, CHU Amiens Nord, Amiens, France, ⁸Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, ⁹service de médecine interne, Hospices Civils de Lyon, groupement Hospitalier Edouard Herriot, Lyon, France, ¹⁰service de médecine interne, Hospice civils de Lyon, Lyon, France, ¹¹Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ¹²Departement of clinical immunology, Hopital Saint Louis, Université Paris Diderot, Sorbonne Paris Cité, Paris, France, ¹³internal medicine, Hopital Foch, Suresnes, France, ¹⁴nephrolohy, CHU Toulouse, Hopital Rangueil, University of Paul Sabatier, Toulouse, France, ¹⁵Service de Médecine Interne, S, CHU Toulouse, Hopital Purpan, University of Paul Sabatier, Toulouse, France, ¹⁶Internal Medicine, Hopital Bichat Claude Bernard, University of Paris Diderot, Sorbonne Paris cité, Paris, FL, France, ¹⁷Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, ¹⁸Internal Medicine, Hopital Jean Verdier, University Paris Nord, Sorbonne Paris Cité, Paris, France, ¹⁹Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France, ²⁰Department of Internal Medicine 1, CHU Pitié-Salpêtrière, Paris, France, ²¹Service de medecine gériatrique, CHU Pitié-Salpêtrière, Paris, France, ²²Pharmacology, CHU Pitié-Salpêtrière, UPMC, University Paris 6, Paris, France, ²³Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ²⁴Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, ²⁵Internal Medicine, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Hydroxychloroquine (HCQ) is now recognized as an important treatment of systemic lupus erythematosus (SLE). Blood HCQ levels ([HCQ]) can be quantified by high performance…
Abstract Number: 1924 • 2014 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products Have Higher Sensitivity Than Serum C3 and C4 Levels in Systemic Lupus Erythematosus
Rosalind Ramsey-Goldman¹, Richard Furie², Chaim Putterman³, Anka Askanase⁴, Jill P. Buyon⁵, Kenneth Kalunian⁶, W. Winn Chatham⁷, E Massarotti⁸, Kyriakos A. Kirou⁹, A. Weinstein¹⁰, Puja Chitkara¹¹, Susan Manzi¹², Joe Ahearn¹³, Leilani Wolover¹⁴, John Conklin¹⁵, Tyler O'Malley¹⁴, Claudia Ibarra¹⁵, Derren Barken¹⁶ and Thierry Dervieux¹⁷, ¹FSM-300, Northwestern University, Chicago, IL, ²Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ³The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Department of Medicine Rhemuatology, Colombia University, New York, NY, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁶UCSD School of Medicine, La Jolla, CA, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Washington Hospital Center, Washington, DC, ¹¹Internal Medicine, Sharp Memorial Hospital, San Diego, CA, ¹²Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ¹³Internal Medicine, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁴Research and Development, Exagen Diagnostics, Inc., Vista, CA, ¹⁵1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ¹⁶Exagen Diagnostics, Inc., Vista, CA, ¹⁷rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Elevated levels of cell bound complement activation products (CBCAPS) have been established as valuable biomarkers in the diagnosis of Systemic Lupus Erythematosus (SLE). In…
Abstract Number: 1896 • 2014 ACR/ARHP Annual Meeting
Validation of a Novel IFN-Regulated Gene Score As Biomarker in Chronic Atypical Neutrophilic Dermatosis with Lipdoystrophy and Elevated Temperature (CANDLE) Patients on Baricitinib, a Janus Kinase 1 /2 Inhibitor, a Proof of Concept
Hanna Kim¹, Steve Brooks², Yin Liu¹, Adriana Almeida de Jesus³, Gina A. Montealegre Sanchez¹, Dawn C. Chapelle¹, Nicole Plass¹, Yan Huang¹ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD, ³Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD
Background/Purpose CANDLE syndrome is a novel autoinflammatory disease with strong IFN response signature. We hypothesize that IFN dysregulation may drive clinical manifestations in CANDLE and…
Abstract Number: 1895 • 2014 ACR/ARHP Annual Meeting
Sacroiliitis at Diagnosis in Children with Juvenile Spondyloarthritis
Pamela Weiss¹, Rui Xiao^2,3 and Nancy Chauvin⁴, ¹Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Pediatrics, Division of Biostatistics, Children's Hospital of Philadelphia, Philadelphia, PA, ³Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁴Radiology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose The prevalence of sacroiliitis in children with juvenile spondyloarthritis (JSpA) at diagnosis is unknown. We aimed to evaluate: 1) the prevalence of sacroiliitis at…
Abstract Number: 1894 • 2014 ACR/ARHP Annual Meeting
Is It Worth It to Include MRI of the Spine in the ASAS Classification Criteria for Axial Spondyloarthritis?
Manouk de Hooge¹, Jean-Baptiste Pialat², Antoine Feydy³, Monique Reijnierse¹, Pascal Claudepierre⁴, Alain Saraux⁵, Maxime Dougados³ and Désirée van der Heijde¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Hôpital Edouard Herriot, Lyon, France, ³Descartes University, Cochin Hospital, Paris, France, ⁴Henri Mondor Teaching Hospital, Creteil, France, ⁵CHU de la Cavale Blanche, Brest Cedex, France
Background/Purpose: Spinal MRI lesions suggestive of axial Spondyloarthritis (axSpA) are not included in the ASAS definition of a positive MRI, but do occur in the…
Abstract Number: 1893 • 2014 ACR/ARHP Annual Meeting
Substantial Structural Lesions on MRI in the Sacroiliac Joints of Patients with Non-Radiographic Axial Spondyloarthritis Even in the Absence of MRI Inflammation
Walter P. Maksymowych¹, S Wichuk¹, H Jones², A Szumski³, L Marshall⁴, J Bukowski⁵ and RG Lambert⁶, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., Collegeville, PA, ⁶Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Treatment of axial SpA is increasingly aimed at intervention early in the disease course before radiographic sacroiliitis has appeared and when response to treatment…
Abstract Number: 1892 • 2014 ACR/ARHP Annual Meeting
In Vivo Visualization of Cortical Microchannels in Metacarpal Bones in Patients with Cutaneous Psoriasis By High Resolution Peripheral Computed tomography – Detecting Cortical Pathologies before the Clinical Onset of Psoriatic-Arthritis
David Simon¹, Francesca Faustini¹, Arnd Kleyer¹, Judith Haschka¹, David Werner¹, Axel J. Hueber¹, Michael Sticherling², Georg Schett¹ and Juergen Rech¹, ¹Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Dermatology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose Normal bones present cortical micro-channels (CMC), which carry micro-vessels and ensure communication between the bone marrow and the synovial compartment. Only recently these structures…
Abstract Number: 1891 • 2014 ACR/ARHP Annual Meeting
Early MRI Endpoints Provide a Valid Measure of Structural Damage While Reducing Study Duration and Participant Numbers in Rheumatoid Arthritis Clinical Trials
Joshua Baker¹, Philip G. Conaghan², Paul Emery³, Daniel Baker⁴ and Mikkel Østergaard⁵, ¹Medicine/Rheumatology, Philadelphia VA Medical Center, Philadelphia, PA, ²University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Janseen R&D, Spring House, PA, ⁵Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark
Background/Purpose We used data from a large randomized controlled clinical trial of an effective biologic (golimumab, GO-BEFORE study) to compare the associations of disease activity…
Abstract Number: 1890 • 2014 ACR/ARHP Annual Meeting
Consistent Inhibition of Bone Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis
Naoki Ishiguro¹, Yoshiya Tanaka², Hisashi Yamanaka³, Toshiyuki Yoneda⁴, Takeshi Ohira⁵, Naoki Okubo⁶, Harry K. Genant⁷, Desiree van der Heijde⁸ and Tsutomu Takeuchi⁹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Daiich Sankyo Co. Ltd, Tokyo, Japan, ⁶1-2-58, Hiromachi, Daiichi Sankyo Co. Ltd, Tokyo, Japan, ⁷University of California, San Francisco, CCBR-Synarc, Newark, Tiburon, CA, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Denosumab is a fully human monoclonal antibody (IgG2 subclass) that binds specifically to RANKL, inhibits osteoclast-induced bone resorption by preventing the binding of RANKL…
Abstract Number: 1889 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA)-Associated Risk Allele LBH Alters the Function of a Differentially Methylated LBH Enhancer
Deepa Hammaker¹, Gary S. Firestein², Wei Wang³, John W. Whitaker⁴ and Anna-Karin Ekwall⁵, ¹Medicine, University of California San Diego, La Jolla, CA, ²Division of Rheumatology, Allergy and Immunology, University of California at San Diego School of Medicine, La Jolla, CA, ³Chemistry, UCSD, La Jolla, CA, ⁴860 island ave, UCSD, San Diego, CA, ⁵Medicine, UC San Diego, La Jolla, CA
Background/Purpose Recent data suggest that epigenetics, including DNA methylation, contributes to imprinting RA fibroblast-like synoviocytes (FLS) and alters their behavior. To understand how RA-associated risk…
Abstract Number: 1888 • 2014 ACR/ARHP Annual Meeting
PU.1, Mitf, and Their Novel Co-Partner, Eomes, Set up a Transcription Factor Network That Is Critical for Osteoclast Differentiation
Heather Carey¹, Sankha Ghosh¹, Eason Hildreth III², Jennifer Cabrera¹, Dias Kurmashev¹, Wael N. Jarjour³, Ramiro Toribio², Sudarshana Sharma¹ and Michael Ostrowski¹, ¹Molecular and Cellular Biochemistry, The Ohio State University, Columbus, OH, ²Veterinary Clinical Sciences, The Ohio State University, Columbus, OH, ³Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose Osteoclasts are bone resorbing cells which differentiate from myeloid precursors. The crosstalk between osteoblasts and osteoclasts tightly regulates the dynamic and continuous process of…
Abstract Number: 1907 • 2014 ACR/ARHP Annual Meeting
Clinical Evaluation of Anti-Aminoacyl tRNA Synthase Antibodies in Rheumatoid Arthritis Patients
Masakazu Matsushita¹, Ken Yamaji¹, Naoto Tamura² and Yoshinari Takasaki³, ¹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Internal Medicine and Rheumatology,, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Anti-Jo-1 is an autoantibody that is specifically detected in the blood sera of patients with polymyositis/dermatomyositis (PM/DM). The corresponding antigen is known to be…
Abstract Number: 1906 • 2014 ACR/ARHP Annual Meeting
IL-6 Blockade Reduces Circulating N-Terminal Pro-Brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis
Atsuma Nishiwaki¹, Hitomi Kobayashi², Yasuyuki Kobayashi³, Isamu Yokoe¹, Noboru Kitamura², Hidetake Shiraiwa¹, Takamasa Nozaki¹, Hirotake Inomata², Natsumi Ikumi⁴, Kaita Sugiyama¹, Yousuke Nagasawa¹ and Masami Takei⁵, ¹Nihon University School of Medicine, Tokyo, Japan, ²Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ³Radiology, St.Marianna University School of Medicine, Kawasaki, Japan, ⁴Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁵Dept of Med Rheumatology, Nihon University School of Medicine, Itabashi Tokyo, Japan
Background/Purpose Patients with rheumatoid arthritis (RA) have a 1.5–2.0 fold higher risk of developing congestive heart failure (CHF) than the general population. Small increases in…
Abstract Number: 1905 • 2014 ACR/ARHP Annual Meeting
Within-Day Variation and Influence of Physical Exercise on Circulating Galectin-3 in Patients with Rheumatoid Arthritis and Healthy Individuals
Saida Farah Issa¹, Anne Friesgaard Christensen², Tine Lottenburger², Kirsten Junker³, Hanne M. Lindegaard¹, Kim Hoerslev-Petersen⁴ and Peter Junker¹, ¹Department of Rheumatology, Odense University Hospital, Odense, Denmark, ²Department of Rheumatology, Vejle Hospital, Vejle, Denmark, ³Institute of Molecular Medicine, Cardiovascular & Renal Research, University of Southern Denmark, Odense, Denmark, ⁴Rheumatology, Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Graasten, Denmark
Background/Purpose: Galectin-3 has been suggested as a pro-inflammatory mediator in Rheumatoid Arthritis(1). Thus, Galectin-3 is over-expressed in RA-synovitis and bone erosions were significantly decreased in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].